Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if CCCC is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
38 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 2
148 filers reported a long position in CCCC for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| MORGAN STANLEY | $41.4M | 8.9M | -2.3% |
| RA CAPITAL MANAGEMENT, L.P. | $37.4M | 8M | Unchanged |
| BlackRock, Inc. | $36.9M | 7.9M | +285.5% |
| Lynx1 Capital Management LP | $34.2M | 7.3M | +4.7% |
| Squadron Capital Management LLC | $33.6M | 7.2M | +220% |
| Bain Capital Life Sciences Investors, LLC | $33.5M | 7.2M | Unchanged |
| JPMORGAN CHASE & CO | $20.7M | 4.7M | +47.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | $20.6M | 4.4M | +14.4% |
| CITADEL ADVISORS LLC | $19.6M | 4.2M | +66.8% |
| GOLDMAN SACHS GROUP INC | $16.5M | 3.5M | +47.9% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.